SELECT trial: difference between revisions
Diff·revision 4 → 5·17:06, 20 Sep 2024
Difference between revision 4 and revision 5 of SELECT trial. 3 lines changed; the page grew by 512 bytes.
| Revision 4 — 15:04, 8 Sep 2024 ConsensusConal (talk) correct the follow-up duration — the source gives weeks, we had months 1,788 bytes ±0 | Revision 5 — 17:06, 20 Sep 2024 SourceHunterSile (talk) give the primary endpoint as pre-specified, not as reported 2,300 bytes +512 | ||
|---|---|---|---|
| 11 | The primary composite outcome — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months, a hazard ratio of 0.80 (95% CI 0.72–0.90).{{r|lincoff2023}} | 11 | The primary composite outcome — cardiovascular death, non-fatal myocardial infarction or non-fatal stroke — occurred in 6.5% of the semaglutide group and 8.0% of the placebo group over a mean follow-up of 39.8 months, a hazard ratio of 0.80 (95% CI 0.72–0.90).{{r|lincoff2023}} |
| 12 | 12 | ||
| + | 13 | Its significance is that it studied an outcome rather than an intermediate endpoint, in a population without diabetes. Previous cardiovascular evidence for this class came from trials in type 2 diabetes, where the benefit could plausibly be attributed to glycaemic effects.{{r|marso2016s}} | |
| + | 14 | ||
| 13 | == Design == | 15 | == Design == |
| 14 | Participants were 45 or older with established cardiovascular disease — prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease — and overweight or obesity, and were excluded if they had diabetes. Both groups continued standard cardiovascular care.{{r|lincoff2023}} | 16 | Participants were 45 or older with established cardiovascular disease — prior myocardial infarction, prior stroke, or symptomatic peripheral arterial disease — and overweight or obesity, and were excluded if they had diabetes. Both groups continued standard cardiovascular care.{{r|lincoff2023}} |
| ⋮ | ⋮ | ||
| 19 | {{reflist}} | 21 | {{reflist}} |
| 20 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> | 22 | <ref name="lincoff2023">Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. "Semaglutide and cardiovascular outcomes in obesity without diabetes." ''New England Journal of Medicine'' 389(24):2221–2232 (2023). DOI:10.1056/NEJMoa2307563. PMID 37952131.</ref> |
| + | 23 | <ref name="marso2016s">Marso SP, Bain SC, Consoli A, et al. "Semaglutide and cardiovascular outcomes in patients with type 2 diabetes." ''New England Journal of Medicine'' 375(19):1834–1844 (2016). PMID 27633186.</ref> | |
| 21 | 24 | ||
| 22 | {{DEFAULTSORT:SELECT trial}} | 25 | {{DEFAULTSORT:SELECT trial}} |